JBS Announces Proposal to Acquire Remaining Publicly Traded Shares of Pilgrim’s Pride Corporation

JBS Announces Proposal to Acquire Remaining Publicly Traded Shares of Pilgrim’s Pride Corporation

Subject to Approval of Independent and Disinterested Special Committee of PPC Board of Directors and Votes Cast by Holders of the Majority of Unaffiliated PPC Shares

AMSTELVEEN, Netherlands–(BUSINESS WIRE)–
JBS N.V. (“JBS,” “we” or “us”) (NYSE: JBS; B3: JBSS32) today announced that it has submitted a non-binding proposal to the Board of Directors of Pilgrim’s Pride Corporation (NASDAQ: PPC) (“PPC”) to acquire all of the outstanding shares of common stock of PPC that are not owned by JBS or its affiliates for a fixed exchange ratio of 2.086 JBS Class A common shares for each PPC share of common stock (the “Proposed Transaction”), based on the JBS and PPC closing share prices on August 18, 2026 of $13.66 and $28.49, respectively. JBS currently owns approximately 82% of PPC’s common stock.

Jeremiah O’Callaghan, Chairman of the JBS Board of Directors, said, “For over 16 years, JBS and PPC have worked together as PPC has expanded its operations, strengthened its global presence and significantly grown revenue. We believe this proposal offers PPC stockholders the opportunity to continue participating in PPC’s future performance through ownership of JBS shares, with exposure to a larger and more diversified global business. Our long-standing relationship with PPC and familiarity with its team and operations should support continuity for employees, customers and business partners throughout the process. We look forward to engaging constructively with the special committee of PPC’s board of directors and its advisors as they evaluate the proposal.”

JBS believes the business combination offers potential benefits to PPC stockholders, including, among others:

  • Continued participation in PPC’s performance: PPC stockholders will benefit from continued participation in PPC’s business performance as part of a larger, more diversified global multi-protein and prepared foods platform.
  • Simplified organizational structure: PPC stockholders would participate, through their ownership of JBS shares, in the potential benefits of a simplified organizational structure, including savings resulting from the elimination of PPC’s standalone public company costs and more flexible and efficient capital allocation across the group.
  • Access to greater trading liquidity of JBS Class A common shares: PPC stockholders would receive shares of JBS, which has a larger market capitalization and broader institutional investor base than PPC’s current minority public float.

Proposed Transaction Details

The Proposed Transaction is subject to the approval of a special committee of independent and disinterested directors expected to be appointed by the PPC Board of Directors, advised by independent legal and financial advisors.

In addition, JBS expects that the Proposed Transaction will also require the approval of a majority of the votes cast by the shares of PPC common stock that are not owned by JBS or its affiliates, as well as customary closing conditions. The Proposed Transaction does not require approval by JBS shareholders. Following completion of the Proposed Transaction, shares of PPC common stock would no longer be quoted on Nasdaq and shares of PPC common stock would be deregistered.

Advisors

Citi is serving as financial advisor, White & Case LLP is serving as legal advisor and Collected Strategies is serving as strategic communications advisor to JBS.

Forward-Looking Statements

This communication contains certain statements that are not historical facts and are forward-looking statements within the meaning of the U.S. federal securities laws with respect to a proposal which JBS has made to acquire all of the outstanding shares of common stock of PPC that are not owned by JBS or its affiliates (the “Proposed Transaction”), including, without limitation, statements regarding the anticipated benefits of the Proposed Transaction to PPC stockholders. These forward-looking statements generally are identified by the words “estimate,” “project,” “forecast,” “plan,” “believe,” “may,” “expect,” “anticipate,” “intend,” “planned,” “potential,” “could,” “will” and similar terms, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: uncertainties as to whether an agreement in respect of the Proposed Transaction will be negotiated and executed; uncertainties as to whether PPC will cooperate with JBS regarding the Proposed Transaction and whether PPC’s board of directors and any special committee thereof will endorse the Proposed Transaction; uncertainties as to whether the other conditions to the Proposed Transaction will be satisfied; the timing of the Proposed Transaction and whether the Proposed Transaction will be completed; failure to realize contemplated synergies and other benefits from the Proposed Transaction; incurrence of significant costs in connection with the Proposed Transaction; changes in general economic conditions, the global protein and prepared foods industries, stock market trading conditions, foreign exchange rates, tax law requirements, or government regulation; and changes in the market position, businesses, financial condition, results of operations or prospects of JBS and/or PPC. The foregoing list of factors is not exhaustive. Additional information concerning these and other factors can be found in JBS’s and PPC’s filings with the U.S. Securities and Exchange Commission (“SEC”), including JBS’s most recent Quarterly Report on Form 10-Q, Annual Report on Form 20-F and Current Reports on Forms 8-K and 6-K, which may be obtained free of charge from JBS’s website https://ir.jbsglobal.com/ and PPC’s most recent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which may be obtained free of charge from PPC’s website https://ir.pilgrims.com/. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and JBS undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This communication shall not constitute an offer to buy or the solicitation of an offer to sell any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

This communication relates to the Proposed Transaction. In furtherance of this Proposed Transaction and subject to future developments, JBS and, if a negotiated transaction is agreed, PPC, as applicable, may file a registration statement, a proxy statement, a tender offer statement or other documents with the SEC. This communication is not a substitute for any registration statement, proxy statement, tender offer statement or other document JBS and/or PPC may file with the SEC in connection with the Proposed Transaction.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT OR TENDER OFFER STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT JBS, PPC AND THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC by JBS and/or PPC free of charge at www.sec.gov or from JBS.

Participants in Solicitation

This communication is neither a solicitation of a proxy nor a substitute for any proxy statement or other filings that may be made with the SEC should the Proposed Transaction go forward. Nonetheless, JBS and its affiliates and their directors and executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the holders of PPC common stock with respect to the Proposed Transaction. Information about such parties and a description of their interests will be included in the materials that JBS expects will be filed by JBS and/or PPC with the SEC should the Proposed Transaction go forward. These documents (if and when available) may be obtained free of charge from the SEC’s website http://www.sec.gov or from JBS’s website https://ir.jbsglobal.com/.

Investor Contact: [email protected]

U.S. Media Contact:

Ed Hammond, Jim Golden, Tali Epstein

Collected Strategies

[email protected]

JBS Global Media Contact:

Juliano Nobrega

[email protected]

KEYWORDS: Netherlands Europe

INDUSTRY KEYWORDS: Food/Beverage Retail

MEDIA:

Logo
Logo

Saratoga Investment Corp. Prices Public Offering of $85.0 Million 8.00% Notes Due 2031

NEW YORK, NY, Aug. 18, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (the “Company”) (NYSE: SAR) today announced that it has priced an underwritten public offering of $85,000,000 in aggregate principal amount of 8.00% unsecured notes due 2031 (the “Notes”). The offering is expected to close on August 26, 2026, subject to customary closing conditions.

The Notes will mature on August 31, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after August 26, 2028. The Notes will bear interest at a rate of 8.00% per year payable quarterly on February 28, May 31, August 31, and November 30 of each year, beginning November 30, 2026.

The Company has granted the underwriters an option to purchase up to an additional $12,750,000 in aggregate principal amount of Notes. The Notes are expected to be listed on the New York Stock Exchange and to trade thereon within 30 days of the original issue date under the trading symbol “SAX”.

The Company has received an investment grade private rating of “BBB” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.

Egan-Jones is a Nationally Recognized Statistical Rating Organization (NRSRO) and is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP). Egan-Jones is also certified by the European Securities and Markets Authority (ESMA).

Lucid Capital Markets, LLC and Oppenheimer & Co. Inc. are serving as joint book-running managers for this offering. B. Riley Securities, Inc., Clear Street LLC, Compass Point Research & Trading, LLC, Ladenburg Thalmann & Co. Inc., and Maxim Group LLC are serving as lead managers for this offering. InspereX LLC and William Blair & Company, L.L.C. are serving as co-managers for this offering. The Company expects to use the net proceeds from this offering and available cash to redeem in full the Company’s outstanding 6.00% Notes due 2027.

Investors are advised to consider carefully the investment objective, risks and charges and expenses of the Company before investing. The preliminary prospectus supplement dated August 18, 2026, the pricing term sheet dated August 18, 2026, and the accompanying prospectus dated March 11, 2026, each of which has been filed with the Securities and Exchange Commission (the “SEC”), contains a description of these matters and other important information about the Company and should be read carefully before investing.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of, the Notes referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. A registration statement (File No. 333-292765) relating to the Notes was filed and has been declared effective by the SEC.

This offering is being made solely by means of a written prospectus forming part of the effective registration statement and a related preliminary prospectus supplement, which may be obtained for free by visiting the SEC’s website at www.sec.gov  or from any of the following investment banks: Lucid Capital Markets, LLC, Attn: George Mangione, 570 Lexington Avenue, 40th Floor, New York, NY 10022 (telephone number (646) 362-3098), or by e-mailing [email protected];  or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at [email protected]

About Saratoga Investment Corp.

Saratoga Investment Corp. is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. The Company’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. The Company has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, and is externally managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies. The Company owns two active SBIC-licensed subsidiaries, having surrendered its first license after repaying all debentures for that fund following the end of its investment period and subsequent wind-down. Furthermore, it manages a $360 million collateralized loan obligation (“CLO”) fund that is in wind-down and co-manages a joint venture (“JV”) that owns a $400 million collateralized loan obligation (“JV CLO”) fund. It also owns 52% of the Class F notes and 100% of the subordinated notes of the CLO, 87.5% of both the unsecured loans and membership interests of the JV and 87.5% of the Class E-R notes of the JV CLO. The Company’s diverse funding sources, combined with a permanent capital base, enable the Company to provide a broad range of financing solutions.

FORWARD-LOOKING STATEMENTS

Statements included herein contain certain “forward-looking statements” within the meaning of the federal securities laws, including statements with regard to the Company’s Notes offering and the anticipated use of the net proceeds of the offering. Forward-looking statements can be identified by the use of forward looking words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or negative versions of those words, other comparable words or other statements that do not relate to historical or factual matters. The forward-looking statements are based on our beliefs, assumptions and expectations of future events and our future performance, taking into account all information currently available to us. These statements are not guarantees of future events, performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including but not limited to an economic downturn or recession and its impact on the ability of our portfolio companies to operate and the investment opportunities available to us; the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policy and its impact on our portfolio companies and the global economy; interest rate volatility, including the uncertainty relating to the interest rate environment; the impact of supply chain constraints; labor shortages; the elevated levels of inflation; and the impact of geopolitical conditions on our portfolio companies and opportunities available to us, as well as those described from time to time in our filings with the SEC. Any forward-looking statement speaks only as of the date on which it is made. The Company undertakes no duty to update any forward-looking statements made herein, whether as a result of new information, future developments or otherwise, except as required by law.

Contact:

Henri Steenkamp
Saratoga Investment Corp.
212-906-7800



Interstate Power and Light Company Prices Debt Offering

Interstate Power and Light Company Prices Debt Offering

$500 million in senior debentures will be due in 2031

MADISON, Wis.–(BUSINESS WIRE)–
Interstate Power and Light Company (“IPL”), a wholly owned subsidiary of Alliant Energy Corporation (NASDAQ: LNT), announced the pricing of its public offering of $500 million aggregate principal amount of 5.100% senior debentures due 2031. The senior debentures will be due on September 30, 2031. IPL intends to use the net proceeds from this offering to reduce outstanding capital under its receivables purchase and sale program, to reduce outstanding commercial paper, and/or for general corporate purposes. The closing of the offering is expected to occur on August 21, 2026, subject to the satisfaction of customary closing conditions.

The offering was marketed through a group of underwriters consisting of Mizuho Securities USA LLC, PNC Capital Markets LLC, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC as joint book-running managers, and Academy Securities, Inc., Fifth Third Securities, Inc., KeyBanc Capital Markets Inc. and TD Securities (USA) LLC as co-managers.

The offering is being made only by means of a prospectus supplement and accompanying prospectus which are part of a shelf registration statement IPL filed with the Securities and Exchange Commission (the “Commission”). Copies may be obtained by calling Mizuho Securities USA LLC toll free at 1-866-271-7403, PNC Capital Markets LLC toll free at 1-855-881-0697, U.S. Bancorp Investments, Inc. toll free at 1-877-558-2607 and Wells Fargo Securities, LLC toll free at 1-800-645-3751. Electronic copies of these documents will be available from the Commission’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alliant Energy

Alliant Energy Corporation’s Iowa utility subsidiary, Interstate Power and Light Company (IPL), utilizes the trade name of Alliant Energy (NASDAQ:LNT). The Iowa utility is based in Cedar Rapids, Iowa.

Forward-Looking Statements

This press release includes forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to the proposed offering, the anticipated use of proceeds from the sale of the senior debentures and other risks outlined in IPL’s public filings with the Commission, including IPL’s most recent annual report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All information provided in this news release speaks as of the date hereof. Except as otherwise required by law, IPL undertakes no obligation to update or revise its forward-looking statements.

Media Hotline: (608) 458-4040

Investor Relations: Susan Gille: (608) 458-3956

KEYWORDS: Wisconsin Iowa United States North America

INDUSTRY KEYWORDS: Energy Other Energy Utilities Oil/Gas

MEDIA:

Logo
Logo

MARTEN TRANSPORT DECLARES QUARTERLY DIVIDEND

MONDOVI, Wis., Aug. 18, 2026 (GLOBE NEWSWIRE) — Marten Transport, Ltd. (Nasdaq/GS:MRTN) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.06 per share of common stock. The dividend will be payable on September 30, 2026 to stockholders of record at the close of business on September 16, 2026.

This is Marten’s 65th consecutive quarterly cash dividend. With the payment of this dividend, Marten will have paid a total of $285.9 million in cash dividends, including special dividends totaling $134.9 million in 2021, 2020, 2019 and 2012, since the dividend program was implemented in 2010.

Marten Transport, with headquarters in Mondovi, Wis., is a multifaceted business offering a network of time and temperature-sensitive and dry truck-based transportation and distribution capabilities across the Company’s five distinct business platforms – Temperature-Sensitive and Dry Truckload, Dedicated, Brokerage and MRTN de Mexico. Marten is one of the leading temperature-sensitive truckload carriers in the United States, specializing in transporting and distributing food, beverages and other consumer packaged goods that require a temperature-controlled or insulated environment. The Company offers service in the United States, Mexico and Canada, concentrating on expedited movements for high-volume customers. Marten’s common stock is traded on the Nasdaq Global Select Market under the symbol MRTN.

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including Marten’s current expectations concerning future payment of dividends. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially from those expressed in such forward-looking statements. Important factors known to Marten that could cause actual results to differ materially from those discussed in the forward-looking statements are discussed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Marten undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS: Randy Marten, Chairman of the Board and Chief Executive Officer, Doug Petit, President, and Jim Hinnendael, Executive Vice President and Chief Financial Officer, of Marten Transport, Ltd., 715-926-4216.



Infleqtion to Test Quantum Sensing in Colorado to Advance U.S. Critical Minerals Security

Infleqtion to Test Quantum Sensing in Colorado to Advance U.S. Critical Minerals Security

Field demonstration planned for 2027 aims to use quantum gravity gradiometry to deliver better discovery and mapping of critical mineral deposits underground before costly drilling begins

LOUISVILLE, Colo.–(BUSINESS WIRE)–Infleqtion (NYSE: INFQ), a global leader in quantum computing and quantum sensing powered by neutral-atom technology, announced plans to conduct a field test of its quantum gravity gradiometry (QGG) technology in Colorado in 2027, which is expected to demonstrate a new approach to understanding what lies beneath the surface and help strengthen America’s critical-minerals supply chain.

The announcement was made during the grand opening of the Colorado Quantum Innovation Center in Louisville.

Critical minerals are essential to U.S. defense systems, advanced manufacturing, energy infrastructure, and emerging technologies, yet discovering and developing domestic resources remains costly, time-intensive, and uncertain.

“America cannot secure the supply chains it cannot see,” said Matt Kinsella, CEO of Infleqtion. “The first step toward mineral independence is knowing what you actually have. In Colorado, we plan to demonstrate how quantum sensing can provide better subsurface intelligence earlier in the exploration process—helping identify promising geological structures and prioritize where further exploration and drilling should occur.”

The planned field test builds on Infleqtion’s support for the Quantum-Enhanced Critical Minerals Mapping Act of 2026 (H.R. 9646), introduced by Rep. Hurd. The legislation would direct the U.S. Geological Survey to incorporate quantum gravity gradiometry into its Earth Mapping Resources Initiative. Kinsella testified before the House Committee on Natural Resources in July in support of the legislation.

The federal government is placing greater emphasis on critical-minerals independence, supported by recent administration actions to call for accelerating federal planning for the use of quantum sensing technologies.

“America should not have to rely on foreign countries for the critical minerals we need for our economy and national security,” said Congressman Jeff Hurd. “That is why I introduced the Quantum-Enhanced Critical Minerals Mapping Act, to put cutting-edge American technology to work helping us better understand the resources we have here at home. I am glad to see Infleqtion testing this technology in Colorado, and especially pleased that they are looking at potential sites in the Third District. Colorado has long been a leader in both natural resources and innovation, and this is a great example of bringing the two together.”

QGG technology measures extremely small variations in Earth’s gravitational field. Those measurements can reveal differences in underground density and geological structure that may otherwise be difficult to characterize from the surface. Used alongside existing geological and geophysical methods, QGG has the potential to help exploration teams narrow search areas and make more informed decisions before undertaking costly and invasive drilling.

Infleqtion’s quantum sensing technologies are currently being advanced through programs with the U.S. Department of War, NASA, and the UK Royal Navy.

Infleqtion is evaluating several potential field-test locations within Colorado’s Third Congressional District, represented by Rep. Jeff Hurd. Additional details on the Colorado field test, including final site selection and timing, are expected to be announced as the program progresses.

About Infleqtion

Infleqtion, Inc. (NYSE: INFQ) is a global leader in quantum technology, delivering neutral-atom solutions for quantum computing, networking, sensing, and security. With a product portfolio spanning quantum computers, quantum optical clocks, RF receivers, and inertial sensors, Infleqtion’s full-stack approach combines high-performance hardware with the company’s proprietary Superstaq quantum computing software platform.

Infleqtion’s systems are already in use by the U.S. Department of War, NASA, the U.K. government, and in multiple collaborations with NVIDIA. Infleqtion, in collaboration with NVIDIA, published the world’s first demonstration of a materials science application using logical qubits. With operations in the U.S., Europe, and Asia, Infleqtion serves government and commercial customers across the space, defense, energy, finance, and telecommunications sectors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipates,” “believes,” “plans,” “seeks,” “will,” “on track” and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than statements of historical facts, including without limitation statements regarding the expected conduct, timing, site locations and outcomes of the QGG field test, are forward looking statements. These statements are based on Infleqtion’s current expectations, assumptions and projections as of the date of this release and are subject to risks and uncertainties that could cause actual results to differ materially and adversely. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Such risks and uncertainties include, without limitation, those related to Infleqtion’s ability to recognize anticipated benefits of its business combination with Churchill Capital Corp X; the implementation, market acceptance, and success of Infleqtion’s business model, growth strategy, and opportunities, and its ability to commercialize its quantum computing technology; the expected benefits of and ability to maintain and enter into new contracts, awards, and other relationships, partnerships, or collaborations with governments or government entities; the potential for quantum computing technology to achieve quantum advantages; the ability of Infleqtion’s products to meet government counterparties’ and customers’ technical requirements and compliance and regulatory needs; Infleqtion’s ability to obtain and maintain intellectual property protection and not infringe on the rights of others; and other risks and uncertainties described in Infleqtion’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these forward-looking statements except as required by law.

Media Contact

Emily O’Brien

Director of Communications, Infleqtion

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Technology White House/Federal Government State/Local Mining/Minerals Other Policy Issues Natural Resources Research Software Public Policy/Government Science Hardware

MEDIA:

Logo
Logo

Cosan S.A. Announces Material Fact

SÃO PAULO, Aug. 18, 2026 (GLOBE NEWSWIRE) — COSAN S.A. (B3: CSAN3; NYSE: CSAN) (“Cosan” or “Company”), in compliance with the provisions of article 157, paragraph 4, of Law No. 6404/76, and Resolution 44/21 of the Brazilian Securities Commission (Comissão de Valores Mobiliários — CVM), and in continuation of the Material Fact disclosed on August 14, 2026, hereby informs its shareholders and the market in general that it has formally notified the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist the American Depositary Shares (the “ADS”), represented by American Depositary Receipts (the “ADRs”), each representing four common shares, no par value, of Cosan from the New York Stock Exchange (the “NYSE”), pursuant to a resolution adopted by its Board of Directors on August 14, 2026.

This transaction is part of Cosan’s objective to simplify and optimize its capital structure, resulting in cost reductions and a greater focus on its most strategically relevant business areas. The Company will maintain the listing of its common shares on the Novo Mercado segment of B3 S.A. – Brasil, Bolsa, Balcão, where trading of its shares is predominantly concentrated.

Cosan intends to file Form 25 with the U.S. Securities and Exchange Commission (“SEC”) on September 8, 2026 (“Form 25”). Following this timeline, the last day of trading of the ADSs on the NYSE would be on September 18, 2026, it being understood that the timelines described are estimates and depend on the progress of all stages of the process.

Cosan will remain registered under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), complying with its reporting obligations under the Exchange Act following the NYSE delisting. Cosan has not arranged for listing, quotation and/or registration of the ADSs on another securities exchange or quotation medium.

Cosan reserves the right, for any reason, to delay these filings or to withdraw them prior to their effectiveness, and to otherwise change its plans in this regard.

São Paulo, August 18, 2026.

Rafael Bergman

Chief Financial and Investor Relations Officer

No Offer or Solicitation

This Material Fact is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction.

Forward Looking Statements

This Material Fact may contain forward-looking statements which reflect Cosan’s current view on future events and financial and operational development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. Any forward-looking statements contained in this Material Fact speak only as at the date hereof, and Cosan does not assume or undertake any obligation or responsibility to update any forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today welcomed President Donald J. Trump’s latest announcement supporting the accelerated development of ibogaine as a potential medical treatment in the United States.

President Trump announced today that the University of Miami has provided the U.S. Federal Government with its original 1994 ibogaine Investigational New Drug (“IND”) application, which he said could help accelerate ibogaine’s development as a medical treatment in the United States.

The President also highlighted progress since his April Executive Order, including HHS research funding, HHS-VA collaboration, FDA guidance and efforts to expand Right to Try access for veterans.

President Trump concluded his statement with a call for additional companies and institutions to participate in the effort.

“This is what Psyence BioMed was built for,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “The President has made clear that the United States wants serious companies and institutions to step forward and help advance ibogaine. We are ready to answer that call.”

Aufrichtig and Psyence BioMed Chief Financial Officer Warwick Corden-Lloyd are currently in Texas meeting with stakeholders and other leaders in the emerging U.S. ibogaine ecosystem to discuss recent progress, the evolving regulatory and policy environment, and opportunities to advance the responsible clinical development of ibogaine in the United States.

“The timing of the President’s announcement is particularly meaningful as Warwick and I are here in Texas engaging directly with stakeholders who are working to turn this growing momentum into tangible progress,” Aufrichtig added. “There is a real sense of urgency around this work, particularly for veterans, and Psyence BioMed intends to be an active participant in determining what comes next.”

Psyence BioMed has been building a vertically integrated pharmaceutical platform designed to support the regulated clinical development of ibogaine. The Company holds an ownership interest in PsyLabs, a pharmaceutical manufacturing operation producing GMP-compliant psychedelic active pharmaceutical ingredients, including ibogaine hydrochloride. Through PsyLabs, Psyence BioMed has access to pharmaceutical-grade manufacturing capabilities and an existing inventory of GMP-compliant ibogaine hydrochloride to support clinical development.

PsyLabs is a core component of Psyence BioMed’s ibogaine strategy, providing manufacturing infrastructure and pharmaceutical expertise as the United States moves toward establishing regulated pathways for ibogaine research and development.

“The conversation around ibogaine has changed dramatically,” Aufrichtig continued. “This is no longer a discussion taking place at the margins of medicine. The White House, HHS, the VA, FDA, researchers and states are increasingly asking how ibogaine can be studied safely, responsibly and at the standards expected of a pharmaceutical medicine. Those are exactly the questions we have been preparing to help answer.”

Psyence BioMed believes the Administration’s latest action reinforces the growing momentum toward regulated ibogaine development in the United States and the need for pharmaceutical-grade manufacturing, rigorous clinical development and close regulatory engagement.

Learn more about the company at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd.
Email: [email protected]
Media Inquiries: [email protected]
General Information: [email protected]
Phone: +1 416-477-1708

Investor Contact:

Michael Kydd
Investor Relations Advisor
[email protected]

About Psyence BioMed

Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics and the manufacturing of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

About PsyLabs

PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.

PsyLabs operates from an ISO 22000 and GMP-compliant facility, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics. www.psylabs.life

Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.

Forward-looking statements in this communication include statements regarding the possible issuance, timing, scope and effect of any U.S. executive action or other governmental measures relating to ibogaine; the potential for such measures to support or accelerate regulated scientific and clinical research into ibogaine; the therapeutic potential of ibogaine and the development of future regulatory pathways for ibogaine-based products; Psyence BioMed’s ability to support global clinical research and future therapeutic development through its investment in PsyLabs and its GMP-compliant manufacturing capabilities; the Company’s ability to develop, maintain and scale an ethically sourced, sustainable and traceable ibogaine supply chain; and the Company’s expected role in supporting future research, development and commercialization activities relating to ibogaine. These forward-looking statements are based on a number of assumptions, including assumptions regarding the development of governmental policy relating to ibogaine, the continuation or expansion of interest in regulated psychedelic research, the availability of lawful research and development pathways, the Company’s ability to maintain required licenses, permits, supply arrangements, third-party relationships and manufacturing capabilities, and the Company’s ability to operate its sourcing and production activities in compliance with applicable legal, regulatory, ethical and environmental standards. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among others, the risk that: (i) any anticipated executive order or other governmental action is not issued, is delayed, or differs from current expectations; (ii) that any such action does not result in expanded research opportunities, clearer regulatory pathways, or any benefit to the Company; (iii) changes in laws, regulations or enforcement priorities in the United States, Southern Africa or other applicable jurisdictions; (iv) the continuing status of ibogaine as a controlled substance in relevant jurisdictions; (v) risks relating to clinical development, regulatory review and approval; (vi) competition and market adoption risks; (vii) and the Company’s ability to maintain compliance with Nasdaq continued listing standards. Additionally, there can be no assurance that the anticipated executive order will be issued, or, if issued, that it will have any particular scope, timing or effect on the Company, its operations, product candidates or applicable regulatory pathways. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to ibogaine stock, inventory, doses or similar references constitute the Company’s best estimates only, as such quantities may vary for several reasons. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

For purposes of this release, references to “GMP-compliant” mean that the relevant product is produced in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards. Such references do not, in themselves, constitute a representation that the product, process or facility has been formally certified, approved or endorsed by any particular regulatory authority unless expressly stated.  In addition, references to “at Source,” or similar expressions refer to supply activities conducted at the cultivation source in Africa. Such references are intended solely to describe the geographic origin and source-location of cultivation and supply activities, and do not, in themselves, constitute a representation regarding regulatory approval, pharmaceutical certification, product registration, or endorsement by any regulatory authority unless expressly stated.



Photronics, Inc. (PLAB) Investors: Notice of Sept. 4, 2026 Deadline to Seek Lead Plaintiff Status in Securities Class Action – HBSS

SAN FRANCISCO, Aug. 18, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a national shareholder rights law firm, is conducting an investigation into Photronics, Inc. (NASDAQ: PLAB) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit, which alleges that Photronics misled investors concerning the demand and outlook for its high-end integrated circuit (IC) photomask product line.


SUBMIT YOUR LOSSES TO HAGENS BERMAN

INVESTOR NOTICE: DEADLINE APPROACHING

Class Period: Dec. 10, 2025 – May 27, 2026
Lead Plaintiff Deadline: Sept. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/plab

Focus of Photronics (PLAB) Securities Class Action:

The pending securities class action alleges that Photronics and its management made materially false and misleading statements regarding the state of its high-end IC product pipeline and global order patterns. The complaint contends that throughout the class period, the company assured investors of global demand and healthy order patterns that would mitigate post-holiday seasonality.

Plaintiffs allege these statements were false because the company’s design release pipeline was experiencing ongoing bottlenecks due to elevated fab usage rates and equipment cost pressures, all of which management allegedly knew or disregarded while maintaining positive financial guidance.

The alleged misrepresentations came to light on May 28, 2026, when Photronics reported financial results for the second quarter of fiscal 2026 that fell short of expectations. The company reported sequential declines in total revenue, an 11% drop in IC revenues, and compressed operating margins, attributing the shortfall to a seasonal recovery that did not materialize following the Chinese New Year, along with unexpected operational bottlenecks.

The market reaction was immediate, with Photronics’ stock price falling 36% in a single trading session and erasing more than $1.1 billion in market capitalization.

“Our investigation is probing the full scope of these pending claims to determine exactly when management knew that demand for its IC products was deteriorating,” said Reed Kathrein, the Hagens Berman partner leading the investigation of the pending suit’s claims.

Investor Rights

Investors who purchased or acquired Photronics securities during the Class Period are encouraged to contact our legal team:

If you’d like more information and answers to other frequently asked questions about the Photronics case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Photronics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm represents investors, whistleblowers, workers, consumers and others in cases achieving results for those harmed by corporate negligence and other wrongdoing. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/47d2c307-bc23-4952-acf1-fe912e7b88c7



Vivmark Residential’s Credit Rating Upgraded to ‘A’ by S&P Global Ratings

Vivmark Residential’s Credit Rating Upgraded to ‘A’ by S&P Global Ratings    

ARLINGTON, Va. & CHICAGO–(BUSINESS WIRE)–
Vivmark Residential (NYSE: VMRK) today announced that S&P Global Ratings raised the Company’s long-term issuer credit rating to ‘A’ with a stable outlook. Vivmark Residential is one of only four REITs with an ‘A’ rating from S&P Global Ratings.

In its rating announcement S&P Global Ratings noted its anticipation that Vivmark Residential will benefit from materially larger scale and operating efficiencies while maintaining a conservative financial policy.

“S&P’s upgrade is an encouraging early affirmation of the financial strength and strategic benefits created by our merger,” said Kevin O’Shea, Vivmark Residential’s Chief Financial Officer. “Vivmark’s scale, conservative balance sheet and disciplined financial policy should enhance our access to capital and provide an incremental advantage as we invest in our operating platform, development pipeline and other opportunities that can create long-term value for shareholders.”

Vivmark Residential was created through a merger of equals between AvalonBay Communities, Inc. and Equity Residential, which was completed on August 17, 2026.

About Vivmark Residential

Vivmark Residential (NYSE: VMRK), an S&P 500 company, sets the mark for what home can be, and our vision is to be the most trusted and best-performing rental housing company in America, one that only gets better as it grows. Our people, scale and capabilities create a self-reinforcing performance cycle that delivers structurally higher growth. With more than 184,000 apartment homes across premier U.S. markets and over $4.4 billion in active development, Vivmark is redefining what rental housing can be. For more details, please visit www.vivmarkresidential.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements, among other things, are based on current expectations, estimates and projections about the industry and markets in which Vivmark Residential (“Vivmark” or, together with its subsidiaries, “we,” “us” or “our”) (f/k/a Equity Residential) operates, as well as beliefs and assumptions of Vivmark. Words such as “anticipate,” “become,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “target,” “seek,” “shall,” “should,” “will,” or “would,” including variations of such words and similar expressions, are intended to identify forward-looking statements. All statements that address operating performance, events or developments that Vivmark expects or anticipates will occur in the future are forward-looking statements, including statements relating to the anticipated synergies, cost savings and other benefits of the Merger (as defined below), integration plans, projected dividends, development net operating income, accretion and value creation, multifamily market conditions, development, redevelopment, acquisition or disposition activity, general conditions in the geographic areas where Vivmark operates and Vivmark’s debt, capital structure and financial position. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors that are difficult to predict and may cause the actual results to differ materially from future results expressed or implied by such forward-looking statements.

Important factors, risks and uncertainties that could cause actual results to differ materially from such plans, estimates or expectations include but are not limited to: the inability to realize the anticipated benefits of the merger (the “Merger”) between AvalonBay Communities, Inc. (“AvalonBay”) and Equity Residential (which Merger formed Vivmark), including as a result of an integration of the two businesses that is unsuccessful or that is more difficult, time-consuming or costly than expected; unknown or inestimable liabilities that arise as a result of the Merger; potential litigation relating to the Merger that could be instituted against Vivmark or its trustees, managers or officers, including resulting expense and the effects of any outcomes related thereto; the risk that disruptions related to the Merger or post-Merger integration and other efforts, and resulting diversion of the attention of Vivmark management from ongoing business operations, will harm Vivmark’s businesses; the possibility that the post-Merger integration of the two businesses may be more expensive to complete than anticipated; potential business uncertainty, including changes to existing business relationships with tenants, employees, joint venture partners and third parties, following the Merger that could affect Vivmark’s financial performance; increased costs of labor and construction material, including as a result of several of the other factors discussed in this section and elsewhere; maintenance of real estate investment trust status, tax structuring and changes in income tax laws and rates; potential failure to secure development opportunities due to an inability to reach agreements with third parties to obtain land at attractive prices or to obtain desired zoning and other local approvals; abandonment or deferment of development opportunities for a number of reasons, including changes in local market conditions, increases in costs of development, increases in the cost of capital or lack of capital availability, resulting in losses; increases in Vivmark’s borrowing costs as a result of changes in interest rates, rising inflation and other factors; construction costs of a community may exceed original estimates; inability to complete construction and lease-up of communities under development or redevelopment on schedule, resulting in increased interest costs and construction costs and a decrease in expected rental revenues; occupancy rates and market rents being adversely affected by competition and local economic and market conditions which are beyond our control; geopolitical conditions and instability, and international trade disputes, including any related tariffs, which may lead to rising inflation, adverse impacts to supply chains, and disruption of, or lack of access to, the capital markets, as well as potential volatility in Vivmark’s share price; our cash flows from operations and access to cost-effective capital potentially being insufficient for the development of our pipeline, which could limit our pursuit of opportunities; an outbreak of disease or other public health event may affect the multifamily industry and general economy; our cash flows potentially being insufficient to meet required payments of principal and interest, and inability to refinance existing indebtedness or the terms of such refinancing may not be as favorable as the terms of existing indebtedness; lack of success in our management of joint ventures and the REIT vehicles that are used with certain joint ventures; a casualty loss, natural disaster or severe weather event, including those caused by climate change; an increase in the level of new multifamily communities construction and development, which may cause heightened competition for tenants and increased pressure on our rental rates; new or existing laws and regulations that adversely impact the markets in which we operate or our business, including those relating to rent control or rent stabilization, or that otherwise limit our ability to increase rents, charge non-rent fees or evict tenants, may impact our revenue or increase our costs; risks related to our reliance on information technology systems, data and artificial intelligence or other automated tools, including cybersecurity incidents and other privacy or data security events, evolving regulation of the collection and use of resident data and of automated or algorithmic tools, and the failure of such systems or tools to perform as intended; our expectations, estimates and assumptions as of the date of this communication regarding legal proceedings changing, including as a result of the Merger; the possibility that we may choose to pay dividends in our shares instead of cash, which may result in shareholders having to pay taxes with respect to such dividends in excess of the cash received, if any; and investments made under our structured investment program may not be repaid as expected or the development may not be completed on schedule, which could require us to engage in litigation, foreclosure actions, and/or first party project completion to recover our investment, which may not be recovered in full or at all in such event; a downgrade in our credit ratings that could increase our borrowing costs and adversely affect our liquidity and ability to access the capital markets, including the commercial paper market; and those risks and uncertainties set forth in Equity Residential’s and AvalonBay’s respective Annual Reports on Form 10-K for the year ended December 31, 2025 under the headings “Forward-Looking Statements” and “Risk Factors,” as such risk factors may be amended, supplemented or superseded from time to time by Vivmark’s subsequent filings with the Securities and Exchange Commission (the “SEC”) and those risks described under “Risk Factors” in the definitive joint proxy statement/prospectus of Equity Residential and AvalonBay, dated July 13, 2026, including the risks related to the combined company described therein, in each case which are available via the SEC’s website at www.sec.gov.

These factors should not be construed as exhaustive and should be read in conjunction with the other forward-looking statements. Forward-looking statements relate only to events as of the date on which the statements are made. Vivmark does not undertake any obligation to publicly update or revise any forward-looking statement except as required by law, whether as a result of new information, future developments or otherwise. If one or more of these or other risks or uncertainties materialize, or if Vivmark’s underlying assumptions prove to be incorrect, Vivmark’s actual results may vary materially from what Vivmark may have expressed or implied by these forward-looking statements. Vivmark cautions not to place undue reliance on any of Vivmark’s forward-looking statements. Furthermore, new risks and uncertainties arise from time to time, and it is impossible for us to predict those events or how they may affect Vivmark. Certain statements in this communication are derived from the standalone 2026 guidance previously reported by AvalonBay and Equity Residential; such guidance speaks only as of the date it was originally issued, and Vivmark does not reaffirm or update such guidance and has not issued guidance for the combined company.

Investor Contacts

Marty McKenna

[email protected]

Matt Grover

[email protected]

Media Contact

Tara Vales

[email protected]

KEYWORDS: Illinois Virginia United States North America

INDUSTRY KEYWORDS: Building Systems Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Latham Group Appoints Todd Antonelli as Chief Commercial Officer

LATHAM, N.Y., Aug. 18, 2026 (GLOBE NEWSWIRE) — Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced the appointment of Todd Antonelli as Chief Commercial Officer.

Mr. Antonelli brings more than 25 years of commercial leadership experience across leading building products organizations, with a track record of driving profitable growth, optimizing sales channels, and leading commercial transformations.

In his role as Chief Commercial Officer, Mr. Antonelli will oversee Latham’s commercial strategy and sales organization, with a focus on strengthening customer relationships, optimizing go-to-market execution, and positioning the Company for continued growth in established markets and accelerated growth in line with our Sand State strategy.

Mr. Antonelli most recently served as Chief Revenue Officer of Cabinetworks Group, the largest privately held cabinet manufacturer in the United States. He led a broad commercial transformation across retail sales, dealer and distributor channels, customer service, and sales operations, strengthening go-to-market execution and building infrastructure to support scalable growth.

Previously, Mr. Antonelli spent nearly a decade with Marvin Windows & Doors, a leading manufacturer of premium windows and doors, most recently serving as Senior Vice President, Sales, and a member of the executive leadership team. During his tenure, he helped nearly triple revenue growth in five years while advancing sales strategy and optimizing distribution channels.

“I am pleased to welcome Todd to Latham,” said Sean Gadd, President and Chief Executive Officer of Latham. “As we enter our next phase of growth, we are focused on building a world-class commercial organization to advance the four pillars of our growth strategy: growing our core business, accelerating conversion from concrete to fiberglass, advancing our autocover business, and pursuing accretive acquisitions. Todd’s deep commercial leadership experience and proven track record of driving profitable growth make him an outstanding addition to our leadership team. I look forward to his contributions as we continue creating value for our customers, dealers, partners, and shareholders.”

Mr. Antonelli holds a Master of Business Administration from California Lutheran University and a Bachelor of Arts from California State University, Chico.

About Latham Group, Inc.

Latham Group, Inc., headquartered in Latham, NY, is the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand. Latham has a coast-to-coast operations platform consisting of approximately 1,900 employees on average across around 40 locations.

Contact:

Lynn Morgen
Casey Kotary
ADVISIRY Partners
[email protected]
212-750-5800